Price adjustment of 12 anticancer drugs in Inner Mongolia, price reduction of Hengrui "capecitabine tablet" reached 54.54%

Yesterday, Inner Mongolia pharmaceutical machinery centralized purchase network released the notice on reducing the purchase price of some drugs (the fourteenth batch), adjusting the prices of 12 drugs, including bortezomib for injection produced by Jiangsu Haosen Pharmaceutical Group Co., Ltd and pegylated recombinant human granulocyte stimulating factor injection produced by Qilu Pharmaceutical Co., Ltd Among them, the "capecitabine tablet" produced by Jiangsu Hengrui has the highest reduction, which has been reduced from 203.11 yuan to 92.4 yuan, with a price reduction rate of 54.54% The price reduction of other products is not significant Recently, the price of drugs has been reduced frequently Home pharmaceutical companies have asked to reduce the price of drugs to meet the market demand As for capecitabine tablets, there are five manufacturers, with fierce competition However, in recent years, the pace of market share has never stopped For the same product with the same specification and dosage form, only since April 2019, as of July 2019, zzz The highest price is produced by Roche, the original manufacturer The bid price is 350.4 yuan The lowest bid price is Zhengda Tianqing, with a price of 91.2 yuan From the table, we can see that the prices of Hengrui, Zhengda Tianqing and Qilu are almost the same It is reasonable that the price of inner Mongolia is reduced this time This article is reprinted by yaozhi.com The copyright belongs to the original author The purpose of reprint is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.